Professor of Surgery, Northeast Ohio Medical University
General Surgery
Dr. Eleftherios P. Mamounas, MD
|
|
Give Review
Dr. Eleftherios P. Mamounas is an expert in the field of General Surgery. He has 1 awards "Fellow (FACS)". Eleftherios P. Mamounas, MD is a published physician. He has 65 publications published. The most current publication "Time-Varying Effects of Breast Cancer Adjuvant Systemic Therapy." He is registered with Medicare and accepts Medicare payments.
Publications
- Time-Varying Effects of Breast Cancer Adjuvant Systemic Therapy.
- Neoadjuvant plus adjuvant bevacizumab in early Breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial.
- Lumpectomy margins: Everything old is new again?
- Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced Breast cancer: NSABP Fou...
- Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 ...
- The importance of systemic therapy in minimizing local recurrence after Breast-conserving surgery: The NSABP experience.
- Timing of determining axillary lymph node status when neoadjuvant chemotherapy is used.
- Chemotherapy for isolated locoregional recurrence of Breast cancer (CALOR): a randomised trial.
- Predicting Degree of Benefit From Adjuvant Trastuzumab in NSABP Trial B-31.
- Preliminary results of centralized HER2 testing in ductal Carcinoma in situ (DCIS): NSABP B-43.
- Lapatinib as a component of neoadjuvant therapy for HER2-positive operable Breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
- Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP ...
- Evaluation of appropriate short-term mammographic surveillance in patients who undergo Breast-conserving Surgery (BCS).
- Pathologic Complete Response of HER-2 Neu-Positive Invasive Ductal Carcinoma and Ductal Carcinoma In Situ following Neoadjuvant Chemotherapy plus Trastuzumab: A Case R...
- Risk of Recurrence and Chemotherapy Benefit for Patients With Node-Negative, Estrogen Receptor-Positive Breast Cancer: Recurrence Score Alone and Integrated With Patho...
- Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Joint Analysis of Data From...
- Impact of the 21-Gene Recurrence Score Assay Compared With Standard Clinicopathologic Guidelines in Adjuvant Therapy Selection for Node-Negative, Estrogen Receptor-Pos...
- Accuracy of a Preoperative Model for Predicting Invasive Breast Cancer in Women with Ductal Carcinoma-in-situ on Vacuum-Assisted Core Needle Biopsy.
- Menstrual history and quality-of-life outcomes in women with node-positive Breast cancer treated with adjuvant therapy on the NSABP B-30 trial.
- Long-term outcomes of invasive ipsilateral Breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS.
- Effect of occult metastases on survival in node-negative Breast cancer.
- Early-stage Breast cancer: new developments and controversies. Preface.
- Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive Breast cancer.
- Longer therapy, iatrogenic amenorrhea, and survival in early Breast cancer.
- Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive Breast cancer: results from NSA...
- A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced Breast cancer.
- Age and lymph node status in Breast cancer: not a straightforward relationship.
- Prognosis after ipsilateral Breast tumor recurrence and locoregional recurrences in patients treated by Breast-conserving therapy in five National Surgical Adjuvant Br...
- Progress on BIG 1-02/IBCSG 27-02/NSABP B-37, a prospective randomized trial evaluating chemotherapy after local therapy for isolated locoregional recurrences of Breast...
- The half century of clinical trials of the National Surgical Adjuvant Breast And Bowel Project.
- Novel intraoperative molecular test for sentinel lymph node metastases in patients with early-stage Breast cancer.
- Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowe...
- Facilitating Breast-conserving surgery and preventing recurrence: aromatase inhibitors in the neoadjuvant and adjuvant settings.
- Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.
- Statement of the science concerning locoregional treatments after preoperative chemotherapy for Breast cancer: a National Cancer Institute conference.
- Is sentinel node biopsy necessary in conservatively treated DCIS?
- Review of Breast cancer clinical trials conducted by the National Surgical Adjuvant Breast Project.
- NSABP B-42: a clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consistin...
- Low locoregional recurrence rate among node-negative Breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy...
- The landmark surgical trials of the National Surgical Adjuvant Breast and Bowel Project.
- Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable Breast cancer:National Surgical Adjuvant Breast...
- Prognosis after ipsilateral Breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant bre...
- Long-term clinical and radiologic results with autologous fat transplantation for Breast augmentation: case reports and review of the literature.
- Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant ther...
- Trastuzumab plus adjuvant chemotherapy for operable HER2-positive Breast cancer.
- Can we approach zero relapse in Breast cancer?
- Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive Breast cancer: results from NSABP B-28.
- Sentinel node biopsy after neoadjuvant chemotherapy in Breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
- Continuing evolution in Breast cancer surgical management.
- American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-posit...
- Tailoring loco-Regional therapy with neoadjuvant chemotherapy: another step in the right direction.
- Estrogen receptor status of primary Breast cancer is predictive of estrogen receptor status of contralateral Breast cancer.
- Accelerated partial Breast irradiation after conservative surgery for Breast cancer.
- Rationale and clinical trial design for evaluating gemcitabine as neoadjuvant and adjuvant therapy for Breast cancer.
- NSABP Breast cancer clinical trials: recent results and future directions.
- Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage Breast cancer.
- Sentinel lymph node biopsy after neoadjuvant systemic therapy.
- American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting.
- A roundtable discussion of aromatase inhibitors as therapy for Breast cancer.
- Neoadjuvant chemotherapy for operable Breast cancer: is this the future?
- Prognosis after rectal Cancer in blacks and whites participating in adjuvant therapy randomized trials.
- Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic Breast cancer: results from NSABP trial BP-58.
- American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive Breast canc...
- Drug Development.
Schools
University of Athens College of Medicine School of Health Science National amp Kapodistrian
McKeesport Hospital
Roswell Park Cancer Institute
University Of Pittsburgh
Procedures Preformed
- Biopsy of Breast
- Breast Reconstruction
- Dressing and-or Debridement of Wound, Infection, or Burn (incl. Negative Pressure Wound Therapy)
- Excision of Breast Tumor
- View All
Conditions Treated
- Abdominal Pain
- Breast Cancer
- Breast Lump
- Carcinoma in Situ
- View All
Doctors Specialties
- General Surgery
Accepted Insurances
Awards
- Fellow (FACS)
Education
-
University of Athens
Drug Facts
| NPI NUMBER | 1174580492 | |
| NPPES Provider LastName | MAMOUNAS | |
| NPPES Provider FirstName | ELEFTHERIOS | |
| NPPES Provider ZIPCode | 328062134 | |
| NPPES Provider State | FL | |
| Specialty Description | Surgical Oncology | |
| Total Claim Count | 40.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 15.0 | |
| Percent Opioid Claims | 37.5 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1174580492 |
| Last Name Of The Provider | MAMOUNAS |
| First Name Of The Provider | ELEFTHERIOS |
| View All |
Similar Doctors
|
|
Dr. Florencio J. Gonzalez, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. David Varnagy, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Alric V. Simmonds, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Richard Arabitg, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Andrea Ferrara, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Giridhar V. Vedula, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Mark K. Soliman, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Kenley B. Davis, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Manuel R. Perez, MD |
|
|
Dr. Gustavo Bustamante, MD |
|
|
Dr. Alvaro M. Bada, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael C. Goldbach, MD |
|
|
Dr. Andrew M. Loudon, MD |
|
|
Dr. Lars S. Nelson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nelson A. Royall, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Jose M. Rios, PA |